Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Other Accumulated Expenses (2016 - 2026)

Anaptysbio filings provide 9 years of Other Accumulated Expenses readings, the most recent being $17.8 million for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $17.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $17.8 million, a N/A change, with the full-year FY2025 number at $16.4 million, down 45.71% from a year prior.
  • Other Accumulated Expenses hit $17.8 million in Q1 2026 for Anaptysbio, up from $16.4 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $30.2 million in Q4 2024 to a low of $16.4 million in Q4 2025.
  • Median Other Accumulated Expenses over the past 3 years was $17.8 million (2026), compared with a mean of $21.5 million.
  • The widest YoY moves for Other Accumulated Expenses: up 45.71% in 2025, down 45.71% in 2025.
  • Anaptysbio's Other Accumulated Expenses stood at $30.2 million in 2024, then tumbled by 45.71% to $16.4 million in 2025, then grew by 8.47% to $17.8 million in 2026.
  • The last three reported values for Other Accumulated Expenses were $17.8 million (Q1 2026), $16.4 million (Q4 2025), and $30.2 million (Q4 2024) per Business Quant data.